^Tedroff J, Torstenson R, Hartvig P, Sonesson C, Waters N, Carlsson A, et al. (April 1998). "Effects of the substituted (S)-3-phenylpiperidine (-)-OSU6162 on PET measurements in subhuman primates: evidence for tone-dependent normalization of striatal dopaminergic activity".Synapse.28 (4):280–7.doi:10.1002/(SICI)1098-2396(199804)28:4<280::AID-SYN3>3.0.CO;2-5.PMID9517836.S2CID2090820.
^Tedroff J, Ekesbo A, Sonesson C, Waters N, Carlsson A (October 1999). "Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease".Neurology.53 (7):1605–6.doi:10.1212/wnl.53.7.1605.PMID10534281.
^Nichols NF, Cimini MG, Haas JV, Staton BA, Tedroff J, Svensson KA (October 2002). "PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease".Neuropharmacology.43 (5):817–24.doi:10.1016/s0028-3908(02)00144-2.PMID12384167.S2CID22101873.
^Tamminga CA, Carlsson A (April 2002). "Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis".Current Drug Targets. CNS and Neurological Disorders.1 (2):141–7.doi:10.2174/1568007024606195.PMID12769623.
^Brandt-Christensen M, Andersen MB, Fink-Jensen A, Werge T, Gerlach J (January 2006). "The substituted (S)-3-phenylpiperidine (-)-OSU6162 reduces apomorphine- and amphetamine-induced behaviour in Cebus apella monkeys".Journal of Neural Transmission.113 (1):11–9.doi:10.1007/s00702-005-0297-1.PMID15795789.S2CID21099503.
^Rung JP, Carlsson A, Markinhuhta KR, Carlsson ML (June 2005). "The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats".Progress in Neuro-Psychopharmacology & Biological Psychiatry.29 (5):833–9.doi:10.1016/j.pnpbp.2005.03.003.PMID15913873.S2CID20868201.
^Natesan S, Svensson KA, Reckless GE, Nobrega JN, Barlow KB, Johansson AM, Kapur S (August 2006). "The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat".The Journal of Pharmacology and Experimental Therapeutics.318 (2):810–8.doi:10.1124/jpet.106.102905.PMID16648369.S2CID9385308.
^Seeman P, Guan HC (February 2007). "Dopamine partial agonist action of (-)OSU6162 is consistent with dopamine hyperactivity in psychosis".European Journal of Pharmacology.557 (2–3):151–3.doi:10.1016/j.ejphar.2006.11.016.PMID17157291.
^Lahti RA, Tamminga CA, Carlsson A (September 2007). "Stimulating and inhibitory effects of the dopamine "stabilizer" (-)-OSU6162 on dopamine D2 receptor function in vitro".Journal of Neural Transmission.114 (9):1143–6.doi:10.1007/s00702-007-0784-7.PMID17612788.S2CID23496944.
^Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A, Carlsson ML (June 2008). "Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization".Journal of Neural Transmission.115 (6):899–908.doi:10.1007/s00702-008-0038-3.PMID18351286.S2CID20687327.
^Benaliouad F, Kapur S, Natesan S, Rompré PP (June 2009). "Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion".European Neuropsychopharmacology.19 (6):416–30.doi:10.1016/j.euroneuro.2009.01.014.PMID19269794.S2CID19419177.
^Dyhring T, Nielsen EØ, Sonesson C, Pettersson F, Karlsson J, Svensson P, et al. (February 2010). "The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties".European Journal of Pharmacology.628 (1–3):19–26.doi:10.1016/j.ejphar.2009.11.025.PMID19919834.
^Carlsson ML, Burstein ES, Kloberg A, Hansson S, Schedwin A, Nilsson M, et al. (November 2011). "I. In vivo evidence for partial agonist effects of (-)-OSU6162 and (+)-OSU6162 on 5-HT2A serotonin receptors".Journal of Neural Transmission.118 (11):1511–22.doi:10.1007/s00702-011-0704-8.PMID21874578.S2CID43580367.
^Burstein ES, Carlsson ML, Owens M, Ma JN, Schiffer HH, Carlsson A, Hacksell U (November 2011). "II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors".Journal of Neural Transmission.118 (11):1523–33.doi:10.1007/s00702-011-0701-y.PMID21866391.S2CID763630.
